Regional Business Development Managers (m/f)

LifeCodexx AG
Job Location
Line-Eid-Straße 3
78467 Konstanz
to be discussed depending on the experience

We  offer:

Working at LifeCodexx AG means being a part of a rapidly growing international life science company with a highly motivated team that has been shaking up the field of prenatal diagnostics since 2012. Today, we are already the market leader in many European countries in the NIPT field.

Job Description

Your main task will be to develop our business by managing new and existing partners in defined markets. This includes commercial and technical aspects as well as partner related internal and external communication. 


Your Role:

  • Manage business partners and maintain excellent relationship on a daily basis
  • Manage the onboarding process of new partners internally and externally
  • Be the interface between LifeCodexx team and Partners
  • Represent Company at congresses & events

Your Profile:

  • Degree in Life Sciences
  • Demonstrated international business experience of minimum 2 years
  • Commercial acumen and ability to solve problems
  • Good selling and negotiation skills
  • Able to work under pressure, meet deadlines and manage priorities in an entrepreneurial setting
  • Fluent in English and German (both verbal and written) is essential
  • Ideally located at our offices in Konstanz (Germany) with extensive travelling of at least 50 %
  • Hands-on mentality and team spirit


How to Apply

Please send us your application (including motivation letter) per email to Andrea Stephinger at


About Our Organization

Headquartered in Konstanz (Germany), LifeCodexx AG has been pioneering non-invasive prenatal testing (NIPT) in Europe since 2012 with the development and launch of the PrenaTest®, Europe’s first NIPT for the determination of the most common chromosomal disorders in unborn children. The test is based on next generation sequencing (NGS) technologies. Most recently, the company has developed a novel qPCR-based NIPT assay for the determination of trisomy 21. The proprietary assay will have breakthrough potential on a global scale, as it offers highest cost-efficiencies and extremely short turnaround times, while providing highest accuracies without any risk for the pregnant woman and the unborn child.

Patricia Fara writes about childcare funding, and women in science and science history at NPR.

National Institute of Environmental Health Sciences researchers have visualized the career paths of former postdocs.

A new survey from the Pew Research Center finds that half of women working in STEM have experienced gender discrimination at work.

A proposal to tax students' tuition waivers no longer appears in the US tax bill, Vox reports.